Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Research output: Contribution to journalReview article

Abstract

Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has changed the treatment landscape in relapsed/refractory B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions. Two CAR-T cell products (axicabtagene ciloleucel and tisagenlecleucel) are currently approved by the United States Food and Drug Administration. A third anti CD19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be United States Food and Drug Administration-approved soon. CAR-T cell-related toxicities, including infections, cytokine release syndrome, and neurotoxicity are potential complications of therapy. With increasing use of CAR-T cells, the mechanism of toxicities and mitigation strategies needs to be developed. Additionally, reasons for CAR-T cell failure and progression following this therapy needs to be further studied. We describe the recent developments in this field, with emphasis on the complications of therapy and factors contributing to toxicities, efficacy, and resistance. We also describe the ongoing research in this field and the newer CAR-T cell constructs that are being developed to counter the challenges that have been identified in this field.

Original languageEnglish (US)
Pages (from-to)751-757
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number12
DOIs
StatePublished - Dec 2019

Fingerprint

Antigen Receptors
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Non-Hodgkin's Lymphoma
CD19 Antigens
United States Food and Drug Administration
Neurotoxicity Syndromes
T-Lymphocytes
Adoptive Immunotherapy
Therapeutics
B-Cell Lymphoma
Clinical Trials
Cytokines
Infection
Research

Keywords

  • Adoptive immunotherapy
  • CAR-T cell toxicity
  • Challenges in CAR-T
  • Chimeric antigen receptor
  • Relapsed non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. / Kallam, Avyakta; Vose, Julie M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 19, No. 12, 12.2019, p. 751-757.

Research output: Contribution to journalReview article

@article{d388e7df778d4385ace9a621e43f512e,
title = "Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma",
abstract = "Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has changed the treatment landscape in relapsed/refractory B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions. Two CAR-T cell products (axicabtagene ciloleucel and tisagenlecleucel) are currently approved by the United States Food and Drug Administration. A third anti CD19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be United States Food and Drug Administration-approved soon. CAR-T cell-related toxicities, including infections, cytokine release syndrome, and neurotoxicity are potential complications of therapy. With increasing use of CAR-T cells, the mechanism of toxicities and mitigation strategies needs to be developed. Additionally, reasons for CAR-T cell failure and progression following this therapy needs to be further studied. We describe the recent developments in this field, with emphasis on the complications of therapy and factors contributing to toxicities, efficacy, and resistance. We also describe the ongoing research in this field and the newer CAR-T cell constructs that are being developed to counter the challenges that have been identified in this field.",
keywords = "Adoptive immunotherapy, CAR-T cell toxicity, Challenges in CAR-T, Chimeric antigen receptor, Relapsed non-Hodgkin lymphoma",
author = "Avyakta Kallam and Vose, {Julie M.}",
year = "2019",
month = "12",
doi = "10.1016/j.clml.2019.09.598",
language = "English (US)",
volume = "19",
pages = "751--757",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "12",

}

TY - JOUR

T1 - Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma

AU - Kallam, Avyakta

AU - Vose, Julie M.

PY - 2019/12

Y1 - 2019/12

N2 - Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has changed the treatment landscape in relapsed/refractory B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions. Two CAR-T cell products (axicabtagene ciloleucel and tisagenlecleucel) are currently approved by the United States Food and Drug Administration. A third anti CD19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be United States Food and Drug Administration-approved soon. CAR-T cell-related toxicities, including infections, cytokine release syndrome, and neurotoxicity are potential complications of therapy. With increasing use of CAR-T cells, the mechanism of toxicities and mitigation strategies needs to be developed. Additionally, reasons for CAR-T cell failure and progression following this therapy needs to be further studied. We describe the recent developments in this field, with emphasis on the complications of therapy and factors contributing to toxicities, efficacy, and resistance. We also describe the ongoing research in this field and the newer CAR-T cell constructs that are being developed to counter the challenges that have been identified in this field.

AB - Adoptive cellular immunotherapy with anti CD19 chimeric antigen receptor (CAR)-T cell has changed the treatment landscape in relapsed/refractory B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions. Two CAR-T cell products (axicabtagene ciloleucel and tisagenlecleucel) are currently approved by the United States Food and Drug Administration. A third anti CD19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be United States Food and Drug Administration-approved soon. CAR-T cell-related toxicities, including infections, cytokine release syndrome, and neurotoxicity are potential complications of therapy. With increasing use of CAR-T cells, the mechanism of toxicities and mitigation strategies needs to be developed. Additionally, reasons for CAR-T cell failure and progression following this therapy needs to be further studied. We describe the recent developments in this field, with emphasis on the complications of therapy and factors contributing to toxicities, efficacy, and resistance. We also describe the ongoing research in this field and the newer CAR-T cell constructs that are being developed to counter the challenges that have been identified in this field.

KW - Adoptive immunotherapy

KW - CAR-T cell toxicity

KW - Challenges in CAR-T

KW - Chimeric antigen receptor

KW - Relapsed non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85073821139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073821139&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.09.598

DO - 10.1016/j.clml.2019.09.598

M3 - Review article

C2 - 31648957

AN - SCOPUS:85073821139

VL - 19

SP - 751

EP - 757

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 12

ER -